Skip to content

Remimazolam Tosilate Versus Propofol for Hemodynamic Stability During Induction of Cardiac Surgery: a Prospective Randomized Controlled Study

Remimazolam Tosilate Versus Propofol for Hemodynamic Stability During Induction of Cardiac Surgery: a Prospective Randomized Controlled Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039273
Enrollment
Unknown
Registered
2020-10-22
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medicine

Interventions

Sponsors

The Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Subjects aged 18-75 years old, regardless of gender; 2. Subjects classified as I - III by ASA; 3. 18 kg / m2 < BMI < 28 kg / m2; 4. Patients who are going to undergo cardiac surgery; 5. The patients participated voluntarily and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. The subjects who are allergic or contraindicated to benzodiazepines, opioids, propofol, naloxone and their drug groups; 2. Patients with severe respiratory diseases (obstructive sleep apnea syndrome, acute respiratory infection, acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, etc.); 3. Patients with uncontrolled hypertension or poorly controlled hypertension (sitting systolic blood pressure >= 160 mmHg and / or diastolic blood pressure >= 100 mmHg in screening period); 4. Subjects with abnormal liver and kidney function: ALT and / or ast exceeding 1.5 times of the upper limit of the medical reference range; creatinine or blood urea nitrogen or blood urea exceeding the upper limit of the medical reference range; 5. Mental patients; 6. Pregnant women or patients preparing for pregnancy in the near future; 7. Patients with long-term alcoholism or use of benzodiazepines and opioids; 8. Patients with difficult airway: Mahalanobis grade III or above.

Design outcomes

Primary

MeasureTime frame
Hemodynamic index;

Secondary

MeasureTime frame
Doses of vasoactive medications;

Countries

China

Contacts

Public ContactYan Zhenyi

The Affiliated Hospital of Guangdong Medical University

453356755@qq.com+86 13763002605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026